Literature DB >> 16702191

PINK1 protein in normal human brain and Parkinson's disease.

S Gandhi1, M M K Muqit, L Stanyer, D G Healy, P M Abou-Sleiman, I Hargreaves, S Heales, M Ganguly, L Parsons, A J Lees, D S Latchman, J L Holton, N W Wood, T Revesz.   

Abstract

Parkinson's disease is a common incurable neurodegenerative disease whose molecular aetiology remains unclear. The identification of Mendelian genes causing rare familial forms of Parkinson's disease has revealed novel proteins and pathways that are likely to be relevant in the pathogenesis of sporadic Parkinson's disease. Recently, mutations in a novel gene, PINK1, encoding a 581 amino acid protein with both mitochondrial targeting and serine/threonine kinase domains, were identified as a cause of autosomal recessive parkinsonism. This provided important evidence for the role of the mitochondrial dysfunction and kinase pathways in neurodegeneration. In this study, we report the first characterization of the PINK1 protein in normal human and sporadic Parkinson's brains, in addition to Parkinson's cases with heterozygous PINK1 mutations. The possible role of the PINK1 protein was also assessed in a number of neurodegenerative diseases characterized by proteinaceous inclusions. For these studies, rabbit polyclonal antibodies were raised against two peptide sequences within the N-terminal hydrophilic loops of PINK1 protein. Using immunohistochemistry and western blotting we were able to demonstrate that PINK1 is a ubiquitous protein expressed throughout the human brain and it is found in all cell types showing a punctate cytoplasmic staining pattern consistent with mitochondrial localization. Fractionation studies of human and rat brain confirm that PINK1 is localized to the mitochondrial membranes. In addition, we show that PINK1 is detected in a proportion of Lewy bodies in cases of sporadic Parkinson's disease and Parkinson's disease associated with heterozygous mutations in the PINK1 gene, which are clinically and pathologically indistinguishable from the sporadic cases. PINK1 was absent in cortical Lewy bodies, in neurofibrillary tangles in Alzheimer's disease, progressive supranuclear palsy and corticobasal degeneration, and in the glial and neuronal alpha-synuclein positive inclusions in multiple system atrophy. These studies provide for the first time in vivo morphological and biochemical evidence to support a mitochondrial localization of PINK1 and underpin the significance of mitochondrial dysfunction in the pathogenesis of nigral cell degeneration in Parkinson's disease.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16702191     DOI: 10.1093/brain/awl114

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  119 in total

1.  Hyperexcitable substantia nigra dopamine neurons in PINK1- and HtrA2/Omi-deficient mice.

Authors:  Matthew W Bishop; Subhojit Chakraborty; Gillian A C Matthews; Antonios Dougalis; Nicholas W Wood; Richard Festenstein; Mark A Ungless
Journal:  J Neurophysiol       Date:  2010-10-06       Impact factor: 2.714

2.  Pink1 kinase and its membrane potential (Deltaψ)-dependent cleavage product both localize to outer mitochondrial membrane by unique targeting mode.

Authors:  Dorothea Becker; Judith Richter; Maja A Tocilescu; Serge Przedborski; Wolfgang Voos
Journal:  J Biol Chem       Date:  2012-04-30       Impact factor: 5.157

Review 3.  The Lewy body in Parkinson's disease and related neurodegenerative disorders.

Authors:  Koichi Wakabayashi; Kunikazu Tanji; Saori Odagiri; Yasuo Miki; Fumiaki Mori; Hitoshi Takahashi
Journal:  Mol Neurobiol       Date:  2012-05-24       Impact factor: 5.590

4.  Impaired neurotransmitter release in Alzheimer's and Parkinson's diseases.

Authors:  Jie Shen
Journal:  Neurodegener Dis       Date:  2010-02-18       Impact factor: 2.977

5.  Co-occurrence of affective and schizophrenia spectrum disorders with PINK1 mutations.

Authors:  Susanne Steinlechner; Jessica Stahlberg; Birgit Völkel; Ana Djarmati; Johann Hagenah; Anja Hiller; Katja Hedrich; Inke König; Christine Klein; Rebekka Lencer
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-01-03       Impact factor: 10.154

6.  Whole-Transcriptome Analysis of Mouse Models with MPTP-Induced Early Stages of Parkinson's Disease Reveals Stage-Specific Response of Transcriptome and a Possible Role of Myelin-Linked Genes in Neurodegeneration.

Authors:  A Kh Alieva; V S Zyrin; M M Rudenok; A A Kolacheva; M V Shulskaya; M V Ugryumov; P A Slominsky; M I Shadrina
Journal:  Mol Neurobiol       Date:  2018-02-03       Impact factor: 5.590

Review 7.  Impairing the mitochondrial fission and fusion balance: a new mechanism of neurodegeneration.

Authors:  Andrew B Knott; Ella Bossy-Wetzel
Journal:  Ann N Y Acad Sci       Date:  2008-12       Impact factor: 5.691

8.  Loss-of-function of human PINK1 results in mitochondrial pathology and can be rescued by parkin.

Authors:  Nicole Exner; Bettina Treske; Dominik Paquet; Kira Holmström; Carola Schiesling; Suzana Gispert; Iria Carballo-Carbajal; Daniela Berg; Hans-Hermann Hoepken; Thomas Gasser; Rejko Krüger; Konstanze F Winklhofer; Frank Vogel; Andreas S Reichert; Georg Auburger; Philipp J Kahle; Bettina Schmid; Christian Haass
Journal:  J Neurosci       Date:  2007-11-07       Impact factor: 6.167

9.  Analysis of exon dosage using MLPA in South African Parkinson's disease patients.

Authors:  Rowena J Keyser; Debbie Lombard; Rene Veikondis; Jonathan Carr; Soraya Bardien
Journal:  Neurogenetics       Date:  2009-12-15       Impact factor: 2.660

Review 10.  The PINK1/Parkin pathway: a mitochondrial quality control system?

Authors:  Alexander J Whitworth; Leo J Pallanck
Journal:  J Bioenerg Biomembr       Date:  2009-12       Impact factor: 2.945

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.